USA flag logo/image

An Official Website of the United States Government

Hollow Fiber Catheter for Drug Delivery into the Prostate

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
96038
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
DK085810
Solicitation Year:
N/A
Solicitation Topic Code:
NIDDK
Solicitation Number:
N/A
Small Business Information
TWIN STAR MEDICAL
1000 Westgate Drive St Paul, MN 55114-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: Hollow Fiber Catheter for Drug Delivery into the Prostate
Agency: HHS
Contract: 1R43DK085810-01
Award Amount: $397,414.00
 

Abstract:

DESCRIPTION (provided by applicant): Significance: Benign Prostatic Hyperplasia (BPH) will become an increasing burden on economic resources with the aging population. Surgical treatment is well established and has provided satisfactory results in 60 - 80% of men. However, it has been associated with significant morbidity and risk of complications; therefore considerable efforts have been directed toward developing alternative minimally invasive treatments. Ablation of the prostate by direct injection has t he potential to significantly reduce expense and morbidity; drugs are available to chemically ablate the tissue. However, though direct injection is a seemingly straightforward approach to the problem, backflow along the needle track and uneven distributio n of drug after injection are significant drawbacks to chemoablation. In contrast to conventional injection needles, the hollow fiber delivery catheter is completely porous; therefore the surface area of tissue in contact with infusate is considerably incr eased. Hypothesis: We hypothesize that use of a hollow fiber catheter for direct infusion into the prostate will result in elimination of backflow and greater volume of distribution than the standard-of-care needle injection. Preliminary Data: We have demo nstrated that the hollow fiber eliminates shear plane and reflux in a tissue phantom gel model, and increases the amount of adenoviral gene transfer by ten times in rodent models (relative to needle infusion). Specific Aims: This project entails preclinica l testing of the hollow fiber catheter for eventual application to human patients with prostate disorders. In Specific Aim 1, we will construct and validate human-scale hollow fiber catheters that are suitable for use in dogs. A widely used clinical inject ion needle will be directly compared to hollow fiber for delivery of dye in a gel model and ex vivo dog prostates. Reflux of infusate and delivery distribution will be quantified along with catheter transmittance properties. In Specific Aim 2, we will use the validated catheters and compare to needles with in vivo injections into a dog prostate. An antibiotic, dye, and contrast solution will be infused and distribution will be determined by evaluation of reflux into bladder by assay (antibiotic), reflux alo ng needle track by fluoroscopy (contrast) and prostate distribution by dye visualization (post procedure prostate removal and sections). Together, these studies will demonstrate the utility of hollow fiber catheters for prostate injections and accelerate t he commercialization of hollow fiber for clinical use. PUBLIC HEALTH RELEVANCE: Drug delivery into the prostate represents a significant obstacle to achieving clinical efficacy. We have developed a novel hollow fiber catheter and shown its potenti al with preliminary studies as a direct injection method for the prostate. In this project, we will conduct preclinical feasibility testing of the hollow fiber catheter in dog prostates in preparation for clinical use of this technology in human patients.

Principal Investigator:

Jim Stice
6123820888
JIM.STICE@TWINSTARMEDICAL.COM

Business Contact:

Jim Stice
jim.stice@twinstarmedical.com
Small Business Information at Submission:

TWIN STAR MEDICAL
TWIN STAR MEDICAL 1000 Westgate Drive St Paul, MN 55114

EIN/Tax ID: 141189283
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No